Sign in Pull a receipt

AVTX

Avalo Therapeutics, Inc.

Healthcare · Biotechnology

$141.06 sample

+1.70 (+1.22%) 1D

Market cap

$797.0B

Price as of

2026-10-29

Latest filing

8-K

Alerts

8

Price$141.06 +0.61% 3M daily closessample

144.80131.17

2026-08-032026-08-252026-09-162026-10-072026-10-29

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 23INSInsider sell: EVP, Operations
Oct 15INSInsider sell: Director
Oct 07INSInsider buy: EVP, Operations
Oct 02INSInsider sell: General Counsel
Sep 25INSInsider sell: Director
Sep 22INSInsider buy: Director
Sep 15INSInsider buy: 10% owner
Sep 07INSInsider buy: EVP, Operations

Sign up to see the real AVTX record →

Company facts

SEC EDGAR registration

Name: Avalo Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +43sample, -100 to +100
Reporting currency: USD

Who is positioning in AVTX

sample

Insiders: 27 insider transactions over 90 days, net selling, $335.9M
Congress: 3 members traded over 90 days
Institutions · 13F: 16 funds hold $17.4B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$38.0B +13.5% y/y

Q4 2024Q3 2026

Inventory$23.7B +15.7% y/y

Q4 2024Q3 2026

Accounts receivable$17.1B +9.9% y/y

Q4 2024Q3 2026

Total debt$44.8B +8.6% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $747.5B -5.9% 3M
Sample peer B: $281.9B +6.7% 3M
Sample peer C: $608.5B +1.6% 3M
Sample peer D: $715.0B +3.5% 3M
Sample peer E: $604.6B -2.0% 3M